Multihance (Gadobenate Dimeglumine)

Gadobenate dimeglumine, the active ingredient in Multihance, is a paramagnetic MRI contrast agent presented as a 0.5 mmol/mL solution for injection for intravenous use. It enhances T1‑weighted magnetic resonance imaging of the brain, spinal cord, liver, cardiovascular system and other abdominal and pelvic structures, providing clearer diagnostic images.

GNH USA supplies Multihance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. All shipments meet EU regulatory standards and are handled under strict quality‑assurance protocols. The product is manufactured under GMP conditions to ensure consistent safety and efficacy.

Multihance is a paramagnetic contrast agent used to improve magnetic resonance imaging across several organ systems.

- Brain and spinal cord MRI: provides enhanced visualization of lesions, tumors and vascular structures. - Liver MRI: improves detection and characterization of focal hepatic lesions. - Cardiovascular MRI: enhances delineation of cardiac chambers, myocardium and vascular anatomy. - Magnetic resonance angiography (MRA): increases signal intensity for clearer arterial and venous mapping. - Abdomen and pelvis MRI: offers better contrast for organs and soft‑tissue assessment.

Gadobenate dimeglumine may be associated with a range of adverse reactions following intravenous administration.

Common Side Effects: - Nausea: mild to moderate feeling of queasiness. - Headache: transient pain in the head region. - Warmth sensation: brief feeling of heat at the injection site. - Injection site pain: mild discomfort where the drug is administered.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Nephrogenic systemic fibrosis: rare fibrotic disorder in patients with severe renal impairment. - Severe hypotension: marked drop in blood pressure that may cause dizziness or fainting. - Cardiac arrest: rare but life‑threatening cessation of heart activity.

Prior to using Multihance, several safety considerations should be evaluated to minimize risk. - Renal function assessment: evaluate glomerular filtration rate, especially in patients with known kidney disease. - Avoid in severe renal impairment: contraindicated in patients with GFR <30 mL/min/1.73 m² due to NSF risk. - Monitor for allergic reactions: observe patients during and after injection for signs of hypersensitivity. - Use with caution in pregnancy: safety not established; weigh diagnostic benefit against potential fetal exposure. - Discontinue if prior gadolinium reaction: avoid re‑exposure in individuals with documented hypersensitivity. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Gadobenate dimeglumine can interact with certain drugs or conditions, influencing safety or efficacy.

Major Interactions (Avoid): - Concurrent use of other gadolinium agents: may increase cumulative gadolinium exposure. - Renally toxic medications (e.g., aminoglycosides, NSAIDs): can exacerbate renal impairment and raise NSF risk.

Moderate Interactions (Monitor Closely): - Iron chelators (e.g., deferoxamine): may alter gadolinium distribution. - Beta‑blockers: may mask hypotensive responses during injection. - Diuretics: can affect renal clearance of the contrast agent.